ArticleThoracic cancer2023

Efficacy and safety of osimertinib plus anlotinib in advanced non-small-cell lung cancer patients after drug resistance.

Mingzhao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.